These issues are discussed in light of data from the BRiTE study, which indicate that the antiangiogenic effects of bevacizumab might persist despite the development of resistance to first-line ...

Amgen and Allergan’s biosimilar of Roche’s cancer blockbuster Avastin has been approved in the EU, but there could be a four-year wait before the drug makes it to the market. The patent ...

“With an indication for use regardless of prior treatment with Avastin, we believe ELAHERE is positioned to become the new standard of care for patients with (FRα)-positive platinum-resistant ...